Features
Photobiomodulation Therapy Delays Dry AMD Progression
Multiwavelength PBM approach shows visual acuity and disease morphology benefits.
By Samuel Asanad, MD, David S. Boyer, MD
Complement Inhibition for Geographic Atrophy
Inhibition of the complement system offers a promising approach to slow GA progression, but challenges remain.
By Aumer Shughoury, MD, Thomas A. Ciulla, MD, MBA
Refining a Deep Learning Model’s Ability to Identify GA Area
The GEODE study evaluated the use of 3D volumetric OCT data to accurately segment the area.
By Simrat K. Sodhi, MSc, MB BChir (Cantab), Hasenin Al-Khersan, MD, David S. Boyer, MD, et al.
Web Exclusives
Functional Outcomes of Current Dry AMD Therapies
Beyond GA lesion growth, consider functional outcomes to provide informed, comprehensive care.
By Kaitlyn Cheng, BA, Raziyeh Mahmoudzadeh, MD, Jessica D. Randolph, MD
Departments
Upfront: What Type of Learner Are You?
By Diana V. Do, MD
New Product Applications: Introducing the Cirrus 6000
The newest generation of Zeiss’s OCT device allows for precise analysis, faster throughput, and smarter decision-making.
By Karen Appold, contributing writer
Coding: Injection Diagnosis Code Challenges
To ensure payment for every drug administered in the practice, knowing and following the payer’s rules is imperative.
By Elizabeth Cifers, MBA, MSW, CHC, CPC
Clinical Trial Update March 2025
Access Retinal Physician's listing of all active clinical trials in AMD, DME, RVO, and uveitis.
Supported Content
Ultra-Widefield Image of the Month
Case Report: Partial Ophthalmic Artery Occlusion
Managing Geographic Atrophy and Intravitreal Injections
Foster a patient-centered environment to improve patient treatment adherence and enhance the quality of life
By Harit Bhatt, MD, MBA, FACS, FASRS
16-Week Data From SALWEEN Fill the Gap for Patients With PCV
By week 16, average BCVA gain was slightly more than seven letters and CST was just over 400 μm.
By Gemmy Cheung, MBBS, FRCOphth, FAMS, MCI, Michael A. Singer, MD